Current development in immunotherapy against cancer has shown great advances with the results of antibodies against checkpoints for non-small cell lung cancer and melanoma and with the use of cellular modifications such as CAR-T for B (CD19+) lymphoid leukemia. This evidence concerns the gene CD19 and non-small cell lung carcinoma.